Jaguar LAA Acquires Laminar Program Assets from Johnson & Johnson

M&A · PartnershipProduct / Tech
โดย PR Newswire·US·Read original
Summary · why it matters

Jaguar LAA, Inc. announced it has acquired assets related to the Laminar program, which targets left atrial appendage closure in patients with non-valvular atrial fibrillation, from Johnson & Johnson. The transaction brings key Laminar program assets together with members of the team responsible for their development into a newly formed, independent company, and Jaguar intends to advance the program through its next stages of development and regulatory review. The Laminar program uses a catheter-based approach and rotational motion to close and eliminate the left atrial appendage while leaving minimal device exposure within the left atrium. Jaguar was formed in partnership with Santé Ventures and members of the Laminar management team, with Santé, management and other investors leading the formation and financing of Jaguar and the transaction with Johnson & Johnson. Financial terms were not disclosed.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Johnson & Johnson
JNJ
± MixedCapitalrelevance

Johnson & Johnson divests Laminar program assets to newly formed Jaguar LAA; financial terms undisclosed, so impact on J&J is unclear.

Off-coverage companies 2

Jaguar LAA, Inc.Private▲ Positive
Capitalrelevance

Jaguar LAA acquires the Laminar left atrial appendage closure program assets and team from Johnson & Johnson, positioning it to advance development and regulatory review.

Santé VenturesPrivate▲ Positive
Capitalrelevance

Santé Ventures led the formation and financing of Jaguar LAA and the transaction with Johnson & Johnson.

© 2026 MarketDXNews